VCP28 protects type 1 diabetic heart against myocardial ischemia/reperfusion injury：role of SIRT1
Zhang Zheng-bin
Su Jie
Xu Bao-ling
Yu Li-ming
Qiu Guang-hao
Dong Miao
Xiong Hong-yan
Liang Hong-liang
Duan Wei-xun
Xin Wei-chuan
Jin Zhen-xiao
Abstract：[ Abstract]:Objective To investigate the protective effect of VCP28 ( adenosine A1 receptor partial agonist) on myocardial is?chemia/reperfusion injury in diabetic rats and to explore its underlying mechanism. Methods Langendorff perfusion of the isolated heart model was established. Type 1 diabetic SD rats were randomly assigned to the following groups ( n = 8):1) Sham group, 2) I/R group and 3) I/R+VCP28 group ( VCP28, adenosine A1 receptor partial agonist;0.1 nmol/L, 10 min before myocardial ichemia) . Left ventricular pressure and left ventricular developed pressure were measured during the whole period. After the reperfusion, the myo?cardial infarction was evaluated. Additionally, the expressions of SIRT1, Ac-foxo1, Ac-p53 and apoptotic related protein were also measured. Results VCP28 treatment markedly improved the cardiac function and reduced myocardial infarction after the reperfusion period. In addition, VCP28 administration also up-regulated the expression of SIRT1 and down-regulated the expressions of Ac-foxo1 and Ac-p53, thus inhibiting the apoptotic signaling. Conclusion This study showed that VCP28 protected the heart against MI/R in?jury by reducing apoptosis possibly through SIRT1 signaling pathway.
Keywords：DiabetesVCP28Myocardial ischemia/reperfusion injurySIRT1apoptosis
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 238-242 )